Mission Wealth Management’s Theriva Biologics TOVX Stock Holding History

Mission Wealth Management’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3	Closed	-$6K	–	290
2018 Q2	$6K	Hold	3	–	–	﹤0.01%	267
2018 Q1	$7K	Hold	3	–	–	﹤0.01%	236
2017 Q4	$12K	Hold	3	–	–	﹤0.01%	232
2017 Q3	$22K	Hold	3	–	–	﹤0.01%	208
2017 Q2	$13K	Hold	3	–	–	﹤0.01%	192
2017 Q1	$15K	Buy	+3	New	+$20.9K	﹤0.01%	196
2016 Q3	–	Sell	-3	Closed	-$42K	–	171
2016 Q2	$42K	Hold	3	–	–	0.01%	163
2016 Q1	$55K	Hold	3	–	–	0.01%	158
2015 Q4	$53K	Hold	3	–	–	0.01%	141
2015 Q3	$53K	Buy	+3	New	+$73.8K	0.02%	134

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Mission Wealth Management's TOVX Position: Q3 2018 in Review

Mission Wealth Management sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 3 shares — an estimated $6K sold.

Mission Wealth Management first reported a position in TOVX in Q3 2015 and held it in 10 quarters. The position peaked at $55K in Q1 2016. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

Mission Wealth Management reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
Mission Wealth Management sold 3 Theriva Biologics shares in Q3 2018, an estimated $6K.
Mission Wealth Management first reported a position in Theriva Biologics in Q3 2015 and held it in 10 quarters.
Mission Wealth Management's Theriva Biologics position peaked at $55K in Q1 2016.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on Mission Wealth Management's 13F filing for Q3 2018, filed 1 Nov 2018.